
Pfizer PFE
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
5.68 B |
Market Cap[1] |
$ 159 B |
EBITDA (LTM) |
$ 6.92 B |
P/E (LTM) |
41.652778 |
P/S (LTM) |
2.678714 |
EPS (LTM) |
0.72 |
Pfizer is a global pharmaceutical company that has been in operation for over 170 years. The company is headquartered in New York City and has a presence in over 150 countries worldwide. Pfizer's mission is to discover, develop, and deliver innovative medicines and vaccines that improve the lives of people around the world.
Pfizer has a diverse portfolio of products that address a range of health conditions, including cardiovascular disease, oncology, inflammation, immunology, and rare diseases. Some of the company's most well-known products include Lipitor, Viagra, and Lyrica.
In addition to developing new treatments, Pfizer is committed to improving access to healthcare for people in need. The company has established partnerships with governments, non-governmental organizations, and healthcare providers to expand access to its medicines and vaccines.
Pfizer is also dedicated to sustainability and reducing its environmental impact. The company has set ambitious goals to reduce greenhouse gas emissions, water consumption, and waste generation across its operations.
As a leading pharmaceutical company, Pfizer is constantly innovating and adapting to meet the changing needs of patients and healthcare providers. With a focus on research and development, access to healthcare, and sustainability, Pfizer is poised to continue making a positive impact on global health for years to come.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Agios Pharmaceuticals
AGIO
|
$ 29.7 | -0.64 % | $ 1.72 B | Nasdaq Global Select Market,SPB | ||
|
NuCana plc
NCNA
|
$ 0.82 | -7.71 % | $ 9.21 B | Nasdaq Global Select Market | ||
|
Equillium
EQ
|
$ 1.1 | -9.5 % | $ 63 M | Nasdaq Global Market | ||
|
Black Diamond Therapeutics
BDTX
|
$ 1.43 | -1.04 % | $ 81.3 M | Nasdaq Global Select Market,SPB | ||
|
Abeona Therapeutics
ABEO
|
$ 2.73 | 4.81 % | $ 145 M | Nasdaq Capital Market | ||
|
ACADIA Pharmaceuticals
ACAD
|
$ 18.0 | -1.77 % | $ 3.03 B | Nasdaq Global Select Market,SPB | ||
|
Atossa Therapeutics
ATOS
|
$ 1.8 | -5.26 % | $ 15.5 M | Nasdaq Capital Market | ||
|
Cleveland BioLabs, Inc.
CBLI
|
- | -7.31 % | $ 49 M | Nasdaq Capital Market | ||
|
Pliant Therapeutics
PLRX
|
$ 0.66 | 0.38 % | $ 40.5 M | Nasdaq Global Select Market | ||
|
Five Prime Therapeutics, Inc.
FPRX
|
- | - | $ 1.77 B | Nasdaq Global Select Market | ||
|
ADC Therapeutics SA
ADCT
|
$ 1.33 | -1.48 % | $ 169 M | NYSE | ||
|
Harmony Biosciences Holdings
HRMY
|
$ 33.1 | 0.29 % | $ 1.9 B | Nasdaq Global Select Market | ||
|
Ardelyx
ARDX
|
$ 3.15 | -1.1 % | $ 759 M | Nasdaq Global Market | ||
|
Akebia Therapeutics
AKBA
|
$ 0.41 | 2.22 % | $ 105 M | Nasdaq Global Market | ||
|
Alector
ALEC
|
$ 2.56 | 1.17 % | $ 264 M | Nasdaq Global Select Market,SPB | ||
|
ALX Oncology Holdings
ALXO
|
$ 0.97 | -3.11 % | $ 52 M | Nasdaq Global Select Market,SPB | ||
|
Amneal Pharmaceuticals
AMRX
|
$ 21.81 | 3.27 % | $ 6.83 B | NYSE | ||
|
Arbutus Biopharma Corporation
ABUS
|
$ 4.12 | 1.6 % | $ 789 M | Nasdaq Global Select Market | ||
|
Agenus
AGEN
|
$ 6.39 | 2.82 % | $ 190 M | Nasdaq Capital Market | ||
|
PolyPid Ltd.
PYPD
|
$ 6.52 | -0.31 % | $ 107 M | Nasdaq Global Select Market | ||
|
AbCellera Biologics
ABCL
|
$ 11.0 | -0.32 % | $ 3.29 B | Nasdaq Global Select Market | ||
|
Artelo Biosciences
ARTL
|
$ 1.5 | -10.71 % | $ 284 K | Nasdaq Global Select Market | ||
|
Immatics N.V.
IMTX
|
$ 6.11 | -2.94 % | $ 748 M | Nasdaq Global Select Market | ||
|
Aptevo Therapeutics
APVO
|
$ 0.45 | -3.45 % | $ 142 K | Nasdaq Capital Market | ||
|
Aligos Therapeutics
ALGS
|
$ 1.3 | -4.41 % | $ 12.9 M | Nasdaq Global Select Market | ||
|
Aclaris Therapeutics
ACRS
|
$ 3.48 | 2.81 % | $ 427 M | Nasdaq Global Select Market | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
$ 28.47 | -0.07 % | $ 4.32 B | Nasdaq Global Select Market,SPB | ||
|
Cellectar Biosciences
CLRB
|
$ 0.89 | -3.51 % | $ 2.32 M | Nasdaq Capital Market | ||
|
Larimar Therapeutics
LRMR
|
$ 3.22 | 7.69 % | $ 268 M | Nasdaq Global Market | ||
|
Biofrontera AG
BFRA
|
- | -8.24 % | $ 105 M | Nasdaq Capital Market | ||
|
Pulmatrix
PULM
|
$ 1.34 | -2.19 % | $ 4.89 B | Nasdaq Global Select Market | ||
|
Intellia Therapeutics
NTLA
|
$ 9.68 | -1.07 % | $ 1.05 B | Nasdaq Global Market,SPB | ||
|
Pharming Group N.V.
PHAR
|
$ 12.48 | 3.51 % | $ 8.6 B | Nasdaq Global Select Market | ||
|
Catabasis Pharmaceuticals, Inc.
CATB
|
- | -6.97 % | $ 657 M | Nasdaq Global Market | ||
|
Capricor Therapeutics
CAPR
|
$ 8.04 | -4.4 % | $ 374 M | Nasdaq Capital Market | ||
|
Amphastar Pharmaceuticals
AMPH
|
$ 29.66 | 1.91 % | $ 1.39 B | Nasdaq Global Select Market | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
$ 14.98 | 1.28 % | $ 12.5 B | NYSE | ||
|
China Biologic Products Holdings, Inc.
CBPO
|
- | 1.68 % | $ 4.65 B | Nasdaq Global Select Market | ||
|
Regeneron Pharmaceuticals
REGN
|
$ 945.14 | -1.32 % | $ 98.9 B | Nasdaq Global Select Market,SPB | ||
|
Aquestive Therapeutics
AQST
|
$ 3.78 | 2.16 % | $ 404 M | Nasdaq Global Market | ||
|
Jaguar Health
JAGX
|
$ 0.35 | -8.69 % | $ 816 K | Nasdaq Capital Market | ||
|
Arvinas
ARVN
|
$ 6.77 | -0.73 % | $ 480 M | Nasdaq Global Select Market,SPB | ||
|
Cerus Corporation
CERS
|
$ 1.95 | 2.63 % | $ 372 M | Nasdaq Global Market | ||
|
Beam Therapeutics
BEAM
|
$ 21.03 | 1.82 % | $ 2.08 B | Nasdaq Global Select Market | ||
|
Inhibrx
INBX
|
$ 68.87 | -7.16 % | $ 3.25 B | Nasdaq Global Select Market | ||
|
Royalty Pharma plc
RPRX
|
$ 68.76 | 0.12 % | $ 29.6 B | Nasdaq Global Select Market | ||
|
Entera Bio Ltd.
ENTX
|
$ 3.24 | 8.0 % | $ 150 M | Nasdaq Capital Market | ||
|
Revolution Medicines
RVMD
|
$ 159.7 | -1.84 % | $ 30.4 B | Nasdaq Global Select Market | ||
|
Flexion Therapeutics, Inc.
FLXN
|
- | - | $ 459 M | Nasdaq Global Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.